Aptose Biosciences Back On Track In The Clinic [Seeking Alpha]
Aptose Biosciences, Inc. - Common Shares (APTO)
Last aptose biosciences, inc. - common shares earnings: 3/10 04:02 pm
Check Earnings Report
US:NASDAQ Investor Relations:
aptose.com/investors
Company Research
Source: Seeking Alpha
Summary Canadian biotech Aptose Biosciences ( APTO ) has a lot of work ahead of it, as the company’s two lead drugs haven’t even completed Phase I testing yet. Even so, the preclinical efficacy and safety data on APTO-253 and CG’806 have looked quite encouraging, and I believe this is a highly speculative opportunity that continues to offer interesting upside. Now with the announcement that the FDA has lifted the clinical hold on APTO-253, Aptose is back on track to have at least one, and possibly two, promising compounds in the clinic before the end of 2018. After A Long Process, APTO-253 Lives Again It has taken almost three years, but Aptose has now successfully resolved the FDA clinical hold that put its lead compound, APTO-253, on ice due to issues with the original formulation that led to pump filters clogging. Management announced on June 29 that the FDA had lifted the hold, and now the company can resume its Phase Ib study in relapsed/refractory AML or high-risk
Show less
Read more
Impact Snapshot
Event Time:
APTO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
APTO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
APTO alerts
High impacting Aptose Biosciences, Inc. - Common Shares news events
Weekly update
A roundup of the hottest topics
APTO
News
- Aptose Biosciences Inc. (NASDAQ: APTO) had its "overweight" rating re-affirmed by analysts at Piper Sandler. They now have a $5.00 price target on the stock.MarketBeat
- Aptose Biosciences Inc. (NASDAQ: APTO) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.MarketBeat
- Aptose Biosciences Inc. (NASDAQ:APTO) Q4 2023 Earnings Call Transcript [Yahoo! Finance]Yahoo! Finance
- Aptose Biosciences Inc. (NASDAQ: APTO) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $23.00 price target on the stock.MarketBeat
- Aptose Reports Results for the Fourth Quarter and Full Year 2023 [Yahoo! Finance]Yahoo! Finance
APTO
Earnings
- 11/9/23 - Beat
APTO
Analyst Actions
- 3/27/24 - HC Wainwright
APTO
Sec Filings
- 4/5/24 - Form 8-K
- 3/26/24 - Form 10-K
- 3/26/24 - Form 8-K
- APTO's page on the SEC website